Life Balance
New targeted drug more than doubles time before HER2-low breast cancer grows
A phase 3 trial of 551 women in China found trastuzumab rezetecan delayed HER2-low breast cancer growth to 16.4 months versus 6.8 on chemotherapy, with more side effects.
29 Oct 2026, 13:51 IST